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Abstract
Background: The aim was to assess the feasibility of a single-centre, single-blind, randomized, crossover design to
explore the effects of two slow-release dopamine agonists, ropinirole and pramipexole, on cued recall in Parkinson’s
disease.
As the design required a switch from the prescribed agonist (pramipexole-to-ropinirole, or ropinirole-to-pramipexole),
the primary objectives were to (a) examine the efficacy of processes and procedures used to manage symptoms during
the washout period and (b) to use cued recall estimates to inform a power calculation for a definitive trial.
Secondary objectives were to assess consent and missing data rates, acceptability of clinical support for the OFF sessions,
experience of the OFF sessions and of agonist switching, barriers-to-participation for patients and informal caregivers.
Methods: Patients were randomized in a 1:1 ratio to two treatment arms and stabilized on each agonist for 6 weeks.
The arms differed only in the sequence in which the agonists were administered. Cued recall was assessed ON
medication and, following a washout period resulting in 93.75% agonist elimination, OFF medication.
Results: A total of 220 patients were screened: 145 were excluded and 75 invitations to participate were sent to eligible
patients. Fifty-three patients declined, 22 consented and 16 completed the study.
There were no serious adverse events, and rates of non-serious adverse events were equivalent between the agonists.
Using the largest standard deviation (SD) of the ON–OFF difference cued recall score (inflated by ~25% to give a
conservative estimate of the SD in a definitive trial) and assuming an effect of at least 10% of the observed range of OFF
medication cued recall scores for either agonist to be clinically important, a main trial requires a sample size of just
under 150 patients.
The consent and missing data rates were 29 and 27% respectively. The washout period and the preparation for the OFF
sessions were acceptable, and the sessions were manageable. The experience of switching was also manageable. Barriers
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to participation included concerns about disease stability, side effects, research process, carer workload and accessibility
of the information sheet.
Conclusions: This study presented challenges to recruitment both in design and execution, and while it was a major
aim of the study to assess this, evaluation of these challenges provided the opportunity to explore how they could be
overcome for future studies.
Trial registration: EudraCT 2012-000801-64
Keywords: Feasibility study, Crossover, Medication withdrawal, Pramipexole PR, Ropinirole MR, Idiopathic Parkinson’s
disease, Cued recall, Safety processes, Acceptability, Barriers to participation
Background
Around 10,000 new cases of Parkinson’s disease (PD) are
diagnosed each year, which indicates that around 1% of
the UK population (an estimated 122,795 people) over
the age of 60 years have PD; this figure is set to rise by
an estimated 28% by 2020 as the population ages [1–4].
PD is diagnosed according to the presence of motor fea-
tures (tremor, rigidity, slowed movement) caused by the
loss of dopamine-producing cells in the midbrain [5–9].
Clinical management is focused on using dopaminergic
replacement drugs to alleviate the cardinal motor signs.
These drugs remediate motor features by increasing avail-
ability of dopamine using levodopa and/or monoamine
oxidase inhibitors, and/or by mimicking the action of
dopamine using second-generation dopamine agonists
such as immediate- or slow-release preparations of prami-
pexole or ropinirole [10–15].
Dopaminergic medication can also have a significant
effect on cognitive function. Evidence indicates that the
requisite dopaminergic state necessary to control motor
signs has the potential to move a patient away from his
or her optimum for certain cognitive functions [16–20].
The relationship between the efficiency of neuronal activity
and the state of dopaminergic modulation in the L-dopa
overdose hypothesis is represented by a Yerkes–Dodson
inverted U-shaped curve, with cognitive functions declin-
ing with deviation away from optimum dopamine levels,
indicated by the centre of the curve. Extrapolating this
model to cued recall implies that dopaminergic medication
has the capacity to both improve and impair this kind of
memory, depending on baseline dopamine levels in the
underlying neural circuitry.
We have recently reported a series of studies in which
cued recall of recently experienced events is impaired in
medicated patients with PD [21–25]. Interpreting these
findings in the context of the L-dopa overdose hypoth-
esis theory implies at least two competing explanations:
either dopaminergic medication is overdosing ‘relatively
normal’ dopamine levels in those brain areas supporting
memory or dopaminergic drugs are reducing the severity
of a PD-related dopamine depletion in the brain areas
supporting memory.
We explored these alternative predictions in an open-
label, nonrandomized pilot of 24 patients with PD in
the early (n = 12) and moderate (n = 12) disease stages
[26]. The patients’ memory was compared to that of a
group of 24 matched healthy controls. To compare the
effects of medication on memory, testing took place
when the patients were in a medicated or ‘ON’ state,
and also on a different occasion following a 24-hour
washout period before the patients took their next
medication, and so were in an unmedicated or ‘OFF’
state. Memory was also assessed on 2 occasions in the
healthy controls, who were not taking any medication,
to control for practice effects. The pilot revealed three
key findings:
Firstly, compared to the healthy control performance,
the PD group exhibited a cued recall deficit when tested
OFF medication, indicating a PD-related memory decline.
Secondly, the severity of the patients’ memory decline
increased when the same patients were tested ON medica-
tion, suggesting that dopaminergic medication increases
the severity of a PD-related decline in memory.
Thirdly, the ON medication decline in memory was
most pronounced in a subset of patients medicated with
the second-generation non-ergot dopamine agonist pra-
mipexole prolonged-release (abbreviated subsequently to
pramipexole), with patients on the second-generation
non-ergot dopamine agonist ropinirole modified-release
(abbreviated to ropinirole) showing a less severe decline.
These preliminary findings were replicated in a further
open-label nonrandomized, parallel-group study of 21
patients with PD medicated with either pramipexole or
ropinirole [27].
While these were intriguing findings that had not pre-
viously been reported in either the scientific or medical
literature, the study design meant that the effects of con-
founding variables, such as demographic and or clinical
differences between the patients on either pramipexole
or ropinirole, could not be ruled out.
Thus, the aim of this study was to assess the feasibility
of a crossover design to explore the effects of pramipex-
ole and ropinirole on memory in patients with idiopathic
PD without cognitive impairment.
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As the design required patients to switch from their
prescribed dopamine agonist (pramipexole-to-ropinirole,
or ropinirole-to-pramipexole), the primary objectives
were to (a) examine the efficacy of processes and proce-
dures used to manage symptoms during the washout
period and (b) to use cued recall estimates to inform a
power calculation for a definitive trial.
The secondary objectives were to assess (i) rates of
consent and missing data; (ii) acceptability of the support
provided for the OFF medication sessions and whether
the OFF session itself was manageable; (iii) the experience
of switching between the investigational medicinal prod-
ucts (IMPs), i.e. ropinirole and pramipexole, assessed at
the mid- and end-of-study clinic visits and in the semi-
structured interview administered at the end of the trial;
and (iv) barriers to participation for eligible patients and
informal carer givers.
Methods
The reporting of the study follows the CONSORT state-
ment recommendations [28].
Design
This 24-month feasibility study was a single-centre,
single-blind, randomized study of two IMPs, ropinirole
and pramipexole, in male and female patients with a
confirmed primary diagnosis of idiopathic PD without
cognitive impairment.
Patients were recruited on one of these agonists, and
randomized in a 1:1 ratio to two treatment arms. The
arms differed only in the sequence the IMPs were ad-
ministered (pramipexole then ropinirole, or ropinirole
then pramipexole).
Patient-participants commenced their first trial IMP
without a ‘run-in’ or washout period. They were stabi-
lized on this IMP for 6 weeks, and then, their memory
was tested on two separate occasions in the following
2 weeks: in one session, the memory was tested 90 min
after taking the IMP (ON), and on a separate occasion,
the memory was assessed following 24–48 h of IMP
withdrawal (OFF).
The OFF session was preceded by a withdrawal period
that resulted in 93.75% (four half-lives) IMP elimination.
After four half-lives, the amount of drug remaining
(6.25%) is considered to be negligible regarding its thera-
peutic effects [29].
The order of ON and OFF sessions was counterbalanced.
A CONSORT diagram showing key stages of the study
design is presented in Fig. 1.
Clinical trial authorization
Clinical trial authorization under The Medicines for Human
Use (Clinical Trials) Regulations 2004 S.I. 2004/1031 was
received from the Licensing Authority in November 2012.
Ethical approval and consent
The study was conducted in accordance with the ethical
principles that have their origins in the Declaration of
Helsinki. The patients were sent approved participant in-
vitation letters that included a reply slip and an informa-
tion sheet for consideration. If a patient indicated interest
by sending a positive reply slip, he/she was contacted by
the research nurse and invited to a screening session with
the chief investigator, who was also the principal investiga-
tor in this study.
Written informed consent was obtained at the screen-
ing interview by the chief investigator, with the research
nurse present as the patient advocate. Patients were
given an opportunity to ask any questions. Consent was
obtained before any study procedures took place.
Recruitment
Recruitment commenced in April 2013. The target
population was males and females aged 50–80 years with
idiopathic, sporadic PD as determined by the UK Parkin-
son’s Disease Society Brain Bank Clinical Diagnostic Cri-
teria, with a Hoehn–Yahr disease severity stage of 1–4
[30].
The target number of complete datasets was 50. The
sample size was determined in terms of obtaining suffi-
ciently precise estimates (as represented by the width of
a 95% confidence interval) of key parameters that would
inform a power calculation for a subsequent main trial.
A figure of 50 is supported by reports on sample sizes
for pilots with continuous outcomes [31, 32].
Eligible patients were identified from the sponsor’s
(University Hospital of North Midlands NHS Trust) De-
partment of Neurology using the PD database and clinic
lists, the GPs in Staffordshire (acting as participant iden-
tification sites), the chief investigator’s private practice,
local pharmacies, advertisements in local newspapers
and recruitment talks given to local PD associations.
Patients entered the study on one of the two IMPs
within the approved dosage range. The maximum dos-
age of each IMP, as specified in the summary of product
characteristics, was pramipexole 0.52–3.15 mg once
daily and ropinirole 2–12 mg once daily [33, 34].
Patients were maintained on the same or equivalent
therapeutic dose for the stabilization periods and for the
ON medication research session, using published con-
version norms, unless clinical indications suggested
modification [35].
Randomization procedure
Once the consent form had been signed, the chief inves-
tigator randomized the patient to the treatment arms.
Third-party randomization, in a 1:1 ratio, took place
during the screening clinic visit using a locked system
that automated the random assignment of treatment groups
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to randomization numbers. The third-party randomization
protocol was a web-based programme, hosted by Keele
University, and was on a password-protected site.
The patient’s randomization code was recorded in the
medical records and case report form. This information
was stored on-line, was read-only and could be accessed
by the chief investigator and research nurse at any point
during the trial.
Level and method of blinding
During the trial, the patients and the clinical members
of the research team (chief investigator, research nurse)
were not blind to the medication codes. The patients
could not be blinded as they saw the physical nature of
the tablets, and the chief investigator and research nurse
managing the patients needed to know how to advise
the patients at the beginning of each treatment phase of
the trial, and when switching between the IMPs, and
how to prepare for the medication withdrawal period.
Only the research assistant administering the cued re-
call memory test during the ON and OFF research ses-
sions was blind to the medication codes. The medication
codes were not made available to the research assistant
until each patient had completed the trial, with his/her
data scored and entered into the database.
Outcomes
The two primary outcomes were efficacy of processes and
procedures used to manage symptoms during the washout
period (measured in relation to adverse events) and esti-
mates of cued recall performance (to inform the sample
size calculation). The secondary outcomes were rates of
consent and missing data, acceptability of the support pro-
vided for the OFF medication sessions and whether the
OFF session itself was manageable, the experience of
switching between IMPs (assessed at the semi-structured
interview administered at the end of the trial) and barriers
to participation for eligible patients and informal carer
givers (semi-structured interview).
Enrolment and study visits
Patients completing the feasibility trial were intended to
participate for a maximum period of no longer than
Fig. 1 CONSORT diagram showing key stages of study design
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16 weeks. During this period, they were involved in eight
separate sessions:
 Three involved the chief investigator and research
nurse and took place during research-dedicated
clinics in a UHNM research facility:
○ Screening visit in week 1 (visit 1)
○ Mid-study follow-up appointment, taking place
between weeks 6 and 8 (visit 4)
○ An end-of-study follow-up appointment, between
weeks 14 and 16 (visit 7)
 Four involved the research assistant and took place
in the patient’s home, around 9 or 10 a.m. in the
morning:
○ Separate ON and OFF medication sessions for
the first IMP, between weeks 6 and 7 (visits 2 and 3)
○ Separate ON and OFF medication sessions for
the second IMP, between weeks 13 and 15 (visits 5
and 6)
 One visit with the research assistant followed the end-
of-study clinic visit, for the purposes of completing a
semi-structured interview about participation,
between weeks 14 and 16 (visit 8).
For the ON research session, medication was taken as
usual roughly 60 min before the session commenced.
For the OFF session, medication was delayed prior to the
session. Medication was resumed following completion of
the session, according to criteria discussed with the chief
investigator. The ON medication and OFF medication
sessions for each drug should have taken place during a
7-day window, on separate days separated by at least
3 days. The order of the ON and OFF research sessions
was determined by the randomization programme.
Washout periods
A single washout period, between the first and second
IMP, was used to eliminate a carryover effect. The elim-
ination half-life for each drug is 8–12 h for pramipexole
in older patients, falling at the upper end of the range:
6 h for ropinirole and 3 h for L-dopa and monoamine
oxidase B inhibitors.
To achieve 93.75% elimination of each drug (equating
to four half-lives), the following washout periods were
required: pramipexole, 48 h (4 × 12 h); ropinirole, 24 h
(4 × 6 h); L-dopa and monoamine oxidase B inhibitors,
12 h (4 × 3 h). At the mid-study clinic visit, patients were
given the second IMP, which they took until the end-of-
study visit.
During the washout period, patients continued to take
L-dopa and/or monoamine oxidase B inhibitor as usual.
The half-lives of these drugs are shorter than those of
the IMPs, and therefore, the washout period required for
93.75% elimination of L-dopa and monoamine oxidase
inhibitor (half-life is between 2 and 3 h) is 12 h. L-dopa
and monoamine oxidase inhibitors were withdrawn 12 h
(overnight) before the OFF research session. The OFF
session took place in the morning, following a washout
period resulting in four half-lives of the drug being elim-
inated (i.e. 93.75%).
Data security and monitoring
A research risk assessment of the feasibility trial was carried
out by the chief investigator and the regulatory research as-
sociate from the sponsor’s research and development de-
partment, prior to the preparation of the protocol. The first
risk assessment was assessed as moderate by 1 point ini-
tially (1 point over the low to moderate risk boundary), but
reassessed later as low-risk, requiring minimal mitigation.
Validation procedures included regular data entry checks
performed on a minimum of 25% of complete patient data
by the monitor. All source data and trial documentation
were available for trial-related monitoring. The patients
consented for this within the consent process.
Patients’ contact details were disclosed to the research
assistant, for the purposes of arranging the four home
visits to complete the memory assessment. All patient
data collected by the research assistant were identified
using a unique study code. This same code was used to
enter patient data into the Microsoft Excel© database.
Copies of signed informed consent forms were placed in
the patient’s medical records and originals retained in
the trial file and kept separate from the data.
Monitoring procedures were carried out by the sponsor
and were in accordance with standard operating proce-
dures. The monitor checked the case report forms, trial
master file and other trial documentation for complete-
ness and the compliance of the trial team with the
protocol and good clinical practice (GCP) standards.
The initial monitoring visit occurred before the trial
started to ensure that the trial complied with the protocol
and GCP standards. Further monitoring visits took place
at regular intervals (approximately twice per year), with a
final monitoring visit conducted to close the trial.
Study committees
A steering group was formed comprising a lay chair, lead
researcher (Edelstyn), chief investigator (Ellis), research
nurse representatives, research assistant (Shepherd), phar-
macy representatives, research and development depart-
ment representatives (Longshaw, Watts) and up to four
patient-public representatives.
Membership of the operational group included the
lead researcher (chair), chief investigator, research nurse
representatives, research assistant, trial pharmacists, spon-
sor research and development representatives. The oper-
ational group met on a monthly basis.
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Analytic strategy
Quantitative data
As this was a feasibility study, no hypothesis tests were
performed. Instead, 95% confidence intervals (CIs) are
presented to indicate the precision of calculated estimates
and to present a range of plausible alternative values for
these estimates.
Qualitative data
All patients who completed the trial were invited to par-
ticipate in semi-structured interview to reflect on their
experience of participation.
A barriers-to-participation study was introduced 9 months
into the 18-month recruitment period to explore reasons for
poor recruitment. NRES permission for retrospective
contact of decliners prior to receiving approval was not
obtained. There was no a priori selection of decliners
for interview. All those who agreed were interviewed.
Interview recordings were transcribed by the research
assistant. During the transcription process, initial thoughts
and observation were noted. Accuracy was checked by
listening to each recording while reading through the
respective transcript, and any necessary amendments
were made. The interviews were transcribed into Microsoft
Word© and were analysed using thematic analysis [36].
Initial topic coding was achieved by reading through
the transcripts and detailing basic themes within the text
using the Microsoft Word© comment function. New
themes emerged from the data throughout this process,
and the procedure was therefore repeated to ensure that
text from transcripts that had been read prior to newly




A total of 220 patients with PD were screened for eligibil-
ity (number of patients with PD found among neurology
patients screened). One hundred and forty-five were ex-
cluded, and 75 eligible patients were invited to take
part. Fifty-three patients declined, 22 consented and 16
completed the study. The age distribution at the time
of consent is shown in Table 1.
Information on the number of patients assessed for
eligibility, randomized and discontinued (together with
reasons) and the complete datasets analysed are presented
in a CONSORT diagram in Fig. 2. Ten patients were ran-
domized to treatment arm 1 (pramipexole then ropinirole)
and 12 to treatment arm 2 (ropinirole then pramipexole).
Outcomes
No serious adverse events were reported. Effects of
short-term withdrawal of the IMPs were minimal when
assessed at the mid- and end-of-study visits. A total of
84 non-serious adverse events were reported (plus one
report of medication error), with seven participants ex-
periencing adverse events; as a result, two withdrew from
the study and three were swapped back to their original
dopamine agonist but agreed to stay in the study. There
was one additional case of the IMP being temporarily
stopped due to an adverse event. This enabled the testing
and refinement of adverse event handling and reporting
by the clinical members of the research team. In terms of
adverse events (non-serious events considered to be re-
lated to the IMP by the chief investigator), the rate was
very similar between both groups (pramipexole, n = 28;
ropinirole, n = 30).
Allocation to treatment arm, IMP daily dose, duration
of IMP treatment and details of compliance for each
patient are provided in Table 2. Arm 1 had 3 patients
who discontinued their assigned treatment due to non-
serious adverse events (PD1, PD11, PD21). These pa-
tients were switched to their original dopamine agonist
but agreed to remain in the study to continue the study
processes. Other patients who deviated from their
assigned IMP were PD2 (pramipexole was temporarily
stopped for 8 days, and the patient switched back to
own pre-study supply of ropinirole prior to the mid-study
visit with the chief investigator) and PD9, who ran out of
study medication prior to the mid- and end-of-study visits
and took own supply (however, this patient was receiving
the correct IMPs for the testing sessions). Therefore, PD2,
PD6, PD9, PD10, PD14, PD16 and PD19 fully completed
the study.
Arm 2 had 3 patients who discontinued their assigned
treatment due to non-serious adverse events (PD7, PD18
and PD23). Participant PD7 reverted to his original
dopamine agonist due to adverse events but agreed to
remain in the study to continue the study processes.
However, PD18 and PD23 wished to fully withdraw and
therefore had no further study assessments or visits. Other
participants who deviated from their assigned IMP were
PD24, who discontinued pramipexole due to non-serious
adverse events but after the ON/OFF research session
(therefore, this participant was on ropinirole, not pra-
mipexole, for the end-of-study visit), and PD17, who
switched medications from pramipexole to ropinirole
Table 1 Age distribution (at time of consent)
Age (years) Frequency
51–55 2 (female = 1, male = 1)
56–60 4 (female = 1, male = 3)
61–65 6 (female = 2, male = 4)
66–70 3 (female = 1, male = 2)
71–75 5 (female = 1, male = 4)
76–80 2 (male = 2)
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prior to the end-of-study visit (but after the ON/OFF
session due to attending a private (non-research) ap-
pointment). Therefore PD3, PD4, PD8, PD12, PD17,
PD20, PD22, PD24 and PD25 fully completed the
study.
In total, therefore, 16 participants completed the study
(defined as completing the memory assessment sessions
on their assigned IMP) and 5 completed the end-of-
study interviews with the research assistant.
Owing to the small sample size, the estimates from the
study are necessarily imprecise (as reflected in wide con-
fidence intervals). However, the data suggest that the ef-
fect of pramipexole on cued recall (OFF–ON difference
score) is 0.030 (95% CI −0.192, 0.079). The correspond-
ing effect of ropinirole is 0.007 (95% CI −0.070, 0.084),
indicating a somewhat smaller decrement in recall. It
also appears, from Table 3 and Fig. 3, that patients en-
tering the study on pramipexole are susceptible to both
a pramipexole-related (OFF–ON difference score 0.034,
95% CI −0.067, 0.135) and ropinirole-related (OFF–ON
difference score 0.036, 95% CI −0.144, 0.215) decrement
in cued recall. For those entering the study on ropinir-
ole, pramipexole (OFF–ON difference score 0.027,
95% CI −0.038, 0.091) showed a decrement in cued re-
call, but this did not occur with ropinirole (OFF–ON
difference score −0.016, 95% CI −0.092, 0.061).
If the effects of pramipexole and ropinirole are com-
pared (pramipexole minus ropinirole), there is a small
difference favouring ropinirole (0.023, 95% CI −0.088,
0.134). A crossover trial is potentially subject to a period
effect, and this was assessed by comparing the difference
in effect of the two IMPs, between the first and second
period. The difference was 0.022 (95% CI −0.094, 0.138).
The estimate of pramipexole versus that of ropinirole
adjusted for the period effect is slightly smaller than the
crude estimate, 0.020, 95% CI −0.095, 0.136.
Accordingly, in addition to an analysis adjusting for a
period effect, it would be advisable to utilize blocked
randomization in a future trial, whereby equal numbers
of patients would be allocated to each treatment se-
quence, helping to offset any period effect. This also raises
the issue of including an additional washout period, prior
Fig. 2 CONSORT diagram showing the number of patients assessed for eligibility, randomized, follow-up and complete datasets analysed
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to administration of the first treatment, in order to re-
move the potential effect of pre-randomization IMP.
The standard deviation (SD) of the within-subject dif-
ferences between the two IMPs was 0.208 (95% CI 0.154,
0.322). If this is inflated by approximately 25% to give
0.260 as a conservative estimate of the SD in a subse-
quent definitive trial [30], Table 4 gives the numbers of
subjects required to detect a range of differences in a
fully powered RCT, with statistical power of 0.90 and a
two-tailed significance level of p ≤ 0.05.
The minimum and maximum OFF medication cued re-
call scores for either ropinirole or pramipexole were 0.040
and 0.735, giving a range of 0.695. Assuming an effect of
at least 10% of the observed range of scores (0.070) to be
clinically important, a main study would therefore require
a sample size of just under 150, at the above levels of
power and statistical significance (without accounting for
loss to follow-up).
Secondary outcomes
With regard to the secondary objectives, the consent
and missing data rates were 29% (95% CI 19%, 40%) and
27% (95% CI 9%, 46%), respectively.
The experience of participation from the end of study
interviews with 5 patients completing the study revealed
two main themes, centred on the experience of participa-
tion and the motivation to take part. The washout period
itself, as well as the preparation for the OFF sessions, were
acceptable, and the experience of switching between the
IMPs was manageable. Two main themes were identified:
the experience of participating and motivation to take
part. Both themes, together with each of the subthemes,
are presented in Table 5. All patients contributed to
each of the two main themes, but not necessarily to all
subthemes.
Finally, barriers to participation were explored with 5
patients who declined to take part in the main study and
Table 2 Pre-study dopamine agonist, allocated treatment arm, first and second IMP and daily dose and duration of IMP treatments
Patient study code Pre-study dopamine
agonist
Trial arm First IMP Daily dose (mg) Number of
days on IMP
Second IMP Daily dose (mg) Number of
days on IMP
PD1 RPR 1 PPX 2.1 3 RPRa, b 8 134
PD2 RPR 1 PPX 2.62 58 RPR 10 48
PD3 RPR 2 RPR 6 51 PPX 1.57 58
PD4 RPR 2 RPR 4 40 PPX 1.05 55
PD5 Consented but then withdrew before taking first IMP
PD6 PPX 1 PPX 2.1 64 RPR 8 52
PD7 PPX 2 RPR 10 13 PPXa, b 2.62 97
PD8 RPR 2 RPR 12 54 PPX 3.15 62
PD9 PPX 1 PPX 1.57 62 RPR 6 56
PD10 RPR 1 PPX 2.1 53 RPR 8 68
PD11 PPX 1 PPX 1.05 48 RPRb 4 30
PD12 PPX 2 RPR 10 52 PPX 2.62 56
PD13 Consented but then withdrew before taking first IMP
PD14 PPX 1 PPX 0.52 52 RPR 2 37
PD15 Consented but then withdrew before taking first IMP
PD16 PPX 1 PPX 1.57 63 RPR 6 55
PD17 PPX 2 RPR 6 60 PPX 1.57 37
PD18 PPX 2 RPR 6 3 Withdrew from IMP and study
PD19 RPR 1 PPX 2.1 55 RPR 8 84
PD20 PPX 2 RPR 8 66 PPX 2.1 41
PD21 PPX 1 PPX 3.15 100 RPRb 12 7
PD22 RPR 2 RPR 6 55 PPX 1.57 48
PD23 PPX 2 RPR 8 5 Withdrew from IMP and study
PD24 RPR 2 RPR 6 58 PPX 1.57 37
PD25 RPR 2 RPR 2 68 PPX 0.52 62
PPX pramipexole PR, RPR ropinirole
aWithdrew from study and reverted to pre-study dopamine agonist
bDiscontinued their assigned treatment due to non-serious adverse events, reverted back to pre-study agonist but agreed to remain in study to test study processes
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5 informal carer givers. Four main themes emerged,
which focused on medication concerns relating to stability
and side effects, accessibility of the recruitment materials,
fear of the unknown and carer workload. The four main
themes together with each of the subthemes, along with il-
lustrating quotations, are presented in Table 6. All partici-
pants contributed to each of the four main themes, but
not necessarily to all subthemes.
Discussion
This study presented challenges to recruitment in both
design and execution, and while it was a major aim of
the study to assess this, evaluation of these challenges
also provided the opportunity to explore how these could
be overcome for future studies in this area. The study ne-
cessitated the use of different methods and approaches to
identify and recruit eligible patient-participants. This in-
cluded raising awareness using promotional material in
local newspapers and pharmacies and establishing links
with GP surgeries (Participant Identification Centres)
through the Primary Care Research Network. However,
the recruitment target of 50 was not met. Consequently,
estimates of key parameters are somewhat imprecise; in
particular, the wide confidence interval around the esti-
mated treatment effect between the two IMPs suggests
that this effect could plausibly lie between approxi-
mately –0.10 and 0.14; the suggested minimum clinically
important effect of 0.70 lies within this range but is some-
what larger than the point estimate of approximately 0.20.
The small sample size also means that the probability of
detecting adverse events is reduced [37].
The challenges and mitigations implemented included
the development of a suite of study-specific standard
operating procedures, including a named standard op-
erating procedure controller. Infrastructure to support
clinical trials of medicinal products was not optimum
at study start-up. The organization underwent signifi-
cant changes prior to and during the study. We now
have clinical studies officers in place to support study
Table 3 Effect of pramipexole versus ropinirole on cued recall according to patients’ pre-study dopamine agonist
Pre-study dopamine
agonist
Drug Condition Estimate: mean (SD) Difference (OFF–ON)
Mean (SD) 95% CI
PPX (n = 7) PPX OFF 0.366 (0.137) 0.034 (0.109) −0.067, 0.135
ON 0.331 (0.140)
RPR OFF 0.284 (0.152) 0.036 (0.194) −0.144, 0.215
ON 0.249 (0.173)
RPR (n = 9) PPX OFF 0.417 (0.162) 0.027 (0.084) −0.038, 0.091
ON 0.390 (0.168)
RPR OFF 0.360 (0.155) −0.016 (0.100) −0.092, 0.061
ON 0.376 (0.147)
PPX pramipexole PR, RPR ropinirole, SD standard deviation, CI confidence interval
Fig. 3 Effect of pramipexole (PPX) versus ropinirole (RPR) on cued
recall according to patients’ dopamine agonist on entry to the study
Table 4 Sample sizes for a main study according to a range of
effects
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set-up, which includes early engagement with support
departments and academics that lead clinical trials of
medicinal products (this includes a full risk assessment
by the sponsor, which is now used to support the deci-
sion regarding capability/capacity to sponsor clinical
trials of medicinal products). There are also dedicated
study monitor roles within the department. The barriers-
to-participation study identified four main themes: con-
cerns that changing medication may worsen their PD
symptoms and also fears about side effects; trial accessibil-
ity, e.g. the information sheet was long and too technical;
fear of the research process; and worries about increasing
the work load of spouses/informal carers.
Recruitment challenges are particularly relevant in
older populations [38], and the heterogeneous nature of
PD means that achieving a sufficient homogeneous patient
sample requires the implementation of very effective re-
cruitment strategies. Individuals with PD are typically eld-
erly and disabled; therefore, participation in clinical trials
often requires the assistance of a caregiver, not only with
hospital visits and organizing medication but also in the
decision to participate itself.
For drug trials in particular, patients with PD have
positive perceptions of placebo-controlled trials, although
they are strongly in favour of receiving the active agent
[39]. Furthermore, evidence suggests a preference for trial
designs that include two active agents (or an active com-
parator) over placebo-controlled designs and indicates that
this may facilitate recruitment due to patients being less
likely to experience ‘lessebo’ effects (the negative expecta-
tions associated to the administration of a placebo) [40].
The challenges of conducting research in PD are illus-
trated by a recent on-line 5-item survey by Mathur et al.
[41]. Their aim was to explore patients’ barriers to par-
ticipation and researchers’ challenges in conducting drug
trials in PD. From an estimated sample size exceeding
10,000 people, the proportion of respondents was around
3%. A total of 33 responses were from researchers and 263
from patients. From the researcher perspective, the main
concerns were related to insufficient financial and
Table 5 The main themes and subthemes and illustrative quotations from the end-of-study interviews with 5 patients
Experience of participating Patient information sheet was too long and complicated.
‘Yes, I thought so, I let my husband read it too, but yes, I thought so […] I think there was a lot of
technical language in it, maybe making that clearer would help? […] I guess some people might
get lost in it maybe?’ (patient-participant 2).
The preparation for the OFF medication sessions was acceptable, and the sessions themselves were manageable.
‘The OFF days were interesting to see what I would be like but, not too concerning. It’s basically like when
you forget to take a tablet or miss one by accident you know, which happens I can tell you, and then I will
be out somewhere and will realize […] it was fine, really, it’s no different to when I forget to take them. You
slow down a bit, but you take more care don’t you? […] yes [it was manageable].’ (patient-participant)
‘To be honest, I could tell I was slower, but other than that there isn’t that much difference really. I was
careful, when walking around the house because I knew I was slower.’ (patient-participant 8).
The experience of switching was acceptable to participants.
‘It was okay. I think when I switched there was a day where I was a bit worse than normal, but that could
have been when I was coming off one and starting the next I suppose couldn’t it? But then the following
day I was back to my normal self actually. I didn’t really have any problems.’ (patient-participant 6)
Participation did not have a major impact on the caregiver.
‘Oh not at all. I mean we talked about it before I decided to take part, obviously, as you would. But it didn’t
do anything to him really. I mean, I like to be as independent as I can, while I can.’ (patient-participant 2)
‘No not really, she came with me to the hospital for those times. But I think that is it. She reminded me of
the appointments as well […] Yeah, it’s because she is in control of the diary you see?’ (patient-participant 3)
Motivation to take part Helping someone else.
‘So we need to do these, going back, we are benefitting from things that others have done for us and we
can pass that forward now, for future people. […] I thought it would be good to contribute something
back you know.’ (patient-participant 2)
‘To help someone further down the line […] Because that is why we’ve got the medications we’ve got
now, because those have done it before.’ (patient-participant 12)
Trying a new drug may help their symptoms.
‘No, not really. I was interested to see if the other drug would be better for me, whether I would see any
improvement, or whether I would be worse. Because, I had never tried it before. I was interested to know.’
(patient-participant 6)
‘I hadn’t really thought about it like that, I was hoping it would improve my walking and make me a bit
better actually, as it happened, I couldn’t really tell the difference at all.’ (patient-participant 8)
Concern about their own memory and recognition of the importance of memory research.
‘That’s why I took part, and have taken part previously. Memory is so important, especially to me […] it
feels awful when I forget little things. It’s just little things. But it gets to me […] Well people’s names, is
frustrating, you know it too, it might be someone you know really well. You know what I mean?’
(patient-participant 6)
‘I think about my memory a lot. It’s why I took part […] You want to know if it is getting worse don’t you?
Especially if it’s worse on one tablet […] People don’t really think about that, do they? I would want know
if they were making my memory worse.’ (patient-participant 8)
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administrative support. Of greater interest to our study
was the overlap with Mathur et al.’s patient-reported bar-
riers: fear of potential adverse consequences, misconcep-
tions regarding clinical trial systems, and issues related to
a perceived lack of communication of relevant informa-
tion between the research and patient communities.
To address the generic as well as specific recruitment
problems discussed above, we recommend adoption of
the the ‘QuinteT Recruitment Intervention’ (QRI), which
aims to understand recruitment as it happens and then
develop an action plan to address identified difficulties
and optimize informed consent in collaboration with the
CTU and chief investigator [41]. The QRI uses a com-
bination of standard and innovative qualitative research
methods with some simple quantification to understand
recruitment and identify sources of difficulties.
Conclusion
Recruitment rates to the main feasibility study were disap-
pointing. Patient and informal caregiver concerns clearly
influenced this and can, at least to some extent, be miti-
gated by improved communication, reassurance, exposure
to the research team and awareness-raising. The sponsor
now has improved capability to support CTIMPs. Going
forward, the sponsor together with the research team is in
a position to mitigate these challenges in a subsequent
main trial, particularly in collaboration with a Clinical
Trials Unit. Implementing these measures, together
with integration of the QRI from the outset in order to
prevent difficulties developing, and optimizing recruit-
ment from the start, rather than applying it to an on-
going RCT experiencing recruitment shortfalls where
time to rectify/address recruitment difficulties may be
limited, and increase confidence that realistic recruit-
ment targets, while still challenging, could be achieved.
Delivering safe, effective and cost-effective pharmaco-
logical management of PD is a priority. It is important
to communicate effectively to the patient community the
importance of drug trials in developing new treatments
and to engage patients and informal caregivers in the
communication and promotion of research.
It is important to note that this feasibility study does
not provide and did not seek to provide firm evidence
that dopaminergic medication affects memory. Therefore,
people with PD should not change their medication based
on the results of this study.
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who declined to take part and 5 informal caregivers
Medication concerns A risking to stability: ‘It takes a long time to get stable, I didn’t want to mess with that’ (patient 3).
Previous switching experience: ‘I felt terrible for 6 months’ (patient 1); ‘It was quite hard, I was quite
poorly’ (patient-participant 3); ‘I didn’t want to start having side effects again’ (patient 4).
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Caregiver workload ‘Her getting worse was a problem for me, because it would be a problem for me’ (informal caregiver 3).
‘If I got worse then he would have to help get about you see. I don’t like to ask him to do more for
me’ (patient 3).
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